Compare LND & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LND | LXEO |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | Brazil | United States |
| Employees | 457 | N/A |
| Industry | Farming/Seeds/Milling | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.6M | 396.5M |
| IPO Year | N/A | 2023 |
| Metric | LND | LXEO |
|---|---|---|
| Price | $3.74 | $4.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.44 |
| AVG Volume (30 Days) | 42.0K | ★ 1.0M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.18% | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | $1.65 | N/A |
| Revenue Next Year | $6.42 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.46 | $3.91 |
| 52 Week High | $4.45 | $10.99 |
| Indicator | LND | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 51.36 | 47.48 |
| Support Level | $3.67 | $4.30 |
| Resistance Level | $3.81 | $5.36 |
| Average True Range (ATR) | 0.10 | 0.35 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 50.00 | 26.02 |
Brasilagro - Cia Bras de Prop Agricolas is a Brazil-based company, engaged in the acquisition, development, operation, and sale of rural properties suitable for agricultural activities. The business activity of the firm is operated through Real estate, Grains, Sugarcane, Cattle rising, Cotton, and Other segments. The Grains segment is involved in the production and sale of soybean and corn. The Sugarcane segment includes the sale of raw product. The Real Estate segment presents the P&L from operations carried out in the company's subsidiaries. The Cattle Raising segment consists of producing and selling beef calves after weaning, which characterizes the activity as breeding and the Other segment engages in other corporate activities. The majority of revenue is earned from Grain Segment.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.